NCT00569660View on ClinicalTrials.gov

Ph II Study of Azacitidine in Myelofibrosis

PHASE2CompletedINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Myelofibrosis

Interventions

DRUG

Azacitidine

75 mg/m\^2 subcutaneous daily for 7 days (every 4 week cycle)

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER